Relationship Between Hyperlipidemia, Cardiovascular Disease and Stroke: A Systematic Review

Overview

Journal Curr Cardiol Rev

Publisher Bentham Science Publishers

Specialty Cardiology & Vascular Diseases

Date 2020 Dec 11

PMID 33305711

Citations 75

Authors

Aladeen Alloubani

Refat Nimer

Rama Samara

Affiliations

Soon will be listed here.

Abstract

Background: Globally, dyslipidemia has been shown to be an independent predictor of many cardiovascular and cerebrovascular events, which led to recent advocacy towards dyslipidemia prevention and control as a key risk factor and its prognostic significance to reduce the burden of stroke and myocardial infarction (MI).

Aims: This study aimed to evaluate hyperlipidemia as a risk factor connected with stroke and CVD. Moreover, having identified this risk factor, the study evaluates how hyperlipidemia has been examined earlier and what can be done in the future.

Methods: All prospective studies concerning hyperlipidemia as risk factors for stroke and CVD were identified by a search of PubMed/MEDLINE and EMBASE databases with keywords hyperlipidemia, risk factors, stroke, and cardiovascular disease.

Results: The constant positive association between the incidence of coronary heart disease and cholesterol concentration of LDL is apparent in observational studies in different populations. Thus, the reduction of LDL cholesterol in those populations, particularly with regard to initial cholesterol concentrations, can reduce the risk of vascular diseases. However, the impact of using lipid-lowering drugs, such as statins, has been demonstrated in several studies as an important factor in decreasing the mortality and morbidity rates of patients with stroke and CVD.

Conclusion: After reviewing all the research mentioned in this review, most studies confirmed that hyperlipidemia is a risk factor for stroke and correlated in patients with CVD.

Citing Articles

Seed Extract Attenuates Glycolipid Metabolism Disorder in Hyperlipidemia Mice Through PPAR Signaling Pathway Based on Metabolomics and Network Pharmacology.

Wang M, Yang T, Xiang Y, Pang J, Wang Y, Sun D Foods. 2025; 14(5).

PMID: 40077474 PMC: 11899454. DOI: 10.3390/foods14050770.

Ignored or underestimated - evaluation and treatment of cardiovascular risk factors in patients with adrenal insufficiency.

Wasmuth A, van de Loo I, Domberg J, Harbeck B Endocrine. 2025; .

PMID: 40000548 DOI: 10.1007/s12020-025-04192-0.

The burden of ischemic stroke in Eastern Europe from 1990 to 2021.

Xu J, Hou S, Chen Z, Liu Y, Deng X, Wang C BMC Neurol. 2025; 25(1):74.

PMID: 39987025 PMC: 11846382. DOI: 10.1186/s12883-025-04081-z.

The Impact of Dietary Fiber on Cardiovascular Diseases: A Scoping Review.

Zhang L, Chen Y, Yang Q, Guo J, Zhou S, Zhong T Nutrients. 2025; 17(3).

PMID: 39940301 PMC: 11819994. DOI: 10.3390/nu17030444.

The effect of magnesium supplementation on serum concentration of lipid profile: an updated systematic review and dose-response meta-analysis on randomized controlled trials.

Hariri M, Sohrabi M, Gholami A Nutr J. 2025; 24(1):24.

PMID: 39905454 PMC: 11796098. DOI: 10.1186/s12937-025-01085-w.

References

. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339(19):1349-57. DOI: 10.1056/NEJM199811053391902. View

Kon Koh K, Oh P, Sakuma I, Lee Y, Han S, Shin E . Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia. Int J Cardiol. 2016; 221:342-6. DOI: 10.1016/j.ijcard.2016.07.038. View

Elam M, Ginsberg H, Lovato L, Corson M, Largay J, Leiter L . Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. JAMA Cardiol. 2016; 2(4):370-380. PMC: 5470410. DOI: 10.1001/jamacardio.2016.4828. View

Holmes M, Millwood I, Kartsonaki C, Hill M, Bennett D, Boxall R . Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke. J Am Coll Cardiol. 2018; 71(6):620-632. PMC: 5811927. DOI: 10.1016/j.jacc.2017.12.006. View

. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344(8934):1383-9. View

Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R . Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010; 376(9753):1658-69. PMC: 2988223. DOI: 10.1016/S0140-6736(10)60310-8. View

. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360(9326):7-22. DOI: 10.1016/S0140-6736(02)09327-3. View

Hatmi Z, Jalilian N, Pakravan A . The Relationship Between Premature Myocardial Infarction with TC/HDL-C Ratio Subgroups in a Multiple Risk Factor Model. Adv J Emerg Med. 2019; 3(3):e24. PMC: 6683591. DOI: 10.22114/ajem.v0i0.149. View

Sever P, Dahlof B, Poulter N, Wedel H, Beevers G, Caulfield M . Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre.... Lancet. 2003; 361(9364):1149-58. DOI: 10.1016/S0140-6736(03)12948-0. View

10.

Ridker P, Rifai N, Cook N, Bradwin G, Buring J . Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005; 294(3):326-33. DOI: 10.1001/jama.294.3.326. View

11.

Ravnskov U, Diamond D, Hama R, Hamazaki T, Hammarskjold B, Hynes N . Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review. BMJ Open. 2016; 6(6):e010401. PMC: 4908872. DOI: 10.1136/bmjopen-2015-010401. View

12.

Ingelsson E, Schaefer E, Contois J, McNamara J, Sullivan L, Keyes M . Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA. 2007; 298(7):776-85. DOI: 10.1001/jama.298.7.776. View

13.

De Caterina R, Scarano M, Marfisi R, Lucisano G, Palma F, Tatasciore A . Cholesterol-lowering interventions and stroke: insights from a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2010; 55(3):198-211. DOI: 10.1016/j.jacc.2009.07.062. View

14.

. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984; 251(3):351-64. DOI: 10.1001/jama.1984.03340270029025. View

15.

Khera A, Demler O, Adelman S, Collins H, Glynn R, Ridker P . Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation. 2017; 135(25):2494-2504. PMC: 5490983. DOI: 10.1161/CIRCULATIONAHA.116.025678. View

16.

Jalloh M, Doroudgar S, Ip E . What is the impact of the 2017 cochrane systematic review and meta-analysis that evaluated the use of PCSK9 inhibitors for lowering cardiovascular disease and mortality?. Expert Opin Pharmacother. 2018; 19(7):739-741. DOI: 10.1080/14656566.2018.1464558. View

17.

. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet. 1995; 346(8991-8992):1647-53. View

18.

Habibi-Koolaee M, Shahmoradi L, Niakan Kalhori S, Ghannadan H, Younesi E . Prevalence of Stroke Risk Factors and Their Distribution Based on Stroke Subtypes in Gorgan: A Retrospective Hospital-Based Study-2015-2016. Neurol Res Int. 2018; 2018:2709654. PMC: 6083549. DOI: 10.1155/2018/2709654. View

19.

Philip-Ephraim E, Charidimou A, Kajogbola G . Quadriparesis due to simultaneous occurrence of hemorrhagic and ischemic stroke. Int J Stroke. 2015; 10(2):E11. DOI: 10.1111/ijs.12404. View

20.

Kannel W . Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 1995; 76(9):69C-77C. DOI: 10.1016/s0002-9149(99)80474-3. View